VI
FOLD

Vestcor Inc’s Amicus Therapeutics FOLD Stock Holding History

Vestcor Inc’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.47M Buy
447,412
+190,000
+74% +$2.72M 0.18% 128
2025
Q4 		$3.67M Buy
+257,412
New +$2.53M 0.1% 203

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Vestcor Inc's FOLD Position: Q1 2026 in Review

Vestcor Inc increased its Amicus Therapeutics (FOLD) stake by 74% in Q1 2026, buying an estimated $2.72M and bringing the position to 447,412 shares worth $6.47M. The position accounts for 0.18% of the portfolio, ranked #128.

Vestcor Inc first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Vestcor Inc held 447,412 shares of Amicus Therapeutics worth $6.47M as of Q1 2026.
  • Vestcor Inc bought 190,000 Amicus Therapeutics shares in Q1 2026, an estimated $2.72M.
  • Amicus Therapeutics made up 0.18% of Vestcor Inc's portfolio in Q1 2026, its #128 holding.
  • Vestcor Inc first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Vestcor Inc's 13F filing for Q1 2026, filed 12 May 2026.